Cannabis fails to delayed swell of mixed sclerosis in UK study

<p>LONDON (Reuters) – Cannabis capsules unsuccessful to delayed a <span>progression</span> of <span>multiple sclerosis</span> in a vast British study, traffic a blow to hopes that a drug could yield long-term advantages for patients with a debilitating haughtiness disease.</p>
<p> Despite earnest signs in earlier, shorter studies, researchers found patients who took capsules containing tetrahydrocannabinol (THC), a pivotal active part in cannabis, fared no improved than those given a placebo.</p>
<p> The anticipating is a beating for researchers who suspicion cannabis competence yield a viable therapy in a disease’s delegate on-going stage, when patients have few diagnosis options.</p>
<p> Multiple sclerosis (MS) patients were assessed in a hearing famous as CUPID (cannabinoid use in on-going inflammatory mind disease) on both a incapacity scale administered by neurologists and anot...